Allianz Asset Management
DNA icon

Allianz Asset Management’s Ginkgo Bioworks DNA Stock Holding History

Allianz Asset Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.79M Buy
785,798
+85,282
+12% +$713K 0.01% 1197
2026
Q1 		$4.29M Buy
700,516
+250,728
+56% +$2.09M ﹤0.01% 1235
2025
Q4 		$3.74M Buy
449,788
+257,628
+134% +$2.77M ﹤0.01% 1269
2025
Q3 		$2.8M Buy
+192,160
New +$2.3M ﹤0.01% 1364
2024
Q2 		– Sell
-34,712
Closed -$1.61M – 2148
2024
Q1 		$1.61M Buy
34,712
+6,884
+25% +$356K ﹤0.01% 1260
2023
Q4 		$1.88M Hold
27,828
– – ﹤0.01% 1354
2023
Q3 		$2.01M Hold
27,828
– – ﹤0.01% 1433
2023
Q2 		$2.07K Buy
27,828
+5,000
+22% +$296K ﹤0.01% 2019
2023
Q1 		$1.21M Buy
22,828
+5,922
+35% +$375K ﹤0.01% 1611
2022
Q4 		$1.14M Hold
16,906
– – ﹤0.01% 1463
2022
Q3 		$2.11M Buy
+16,906
New +$2.01M ﹤0.01% 1215

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Allianz Asset Management's DNA Position: Q2 2026 in Review

Allianz Asset Management increased its Ginkgo Bioworks (DNA) stake by 12% in Q2 2026, buying an estimated $713K and bringing the position to 785,798 shares worth $7.79M. The position accounts for 0.01% of the portfolio, ranked #1197.

Allianz Asset Management first reported a position in DNA in Q3 2022 and has held it in 11 quarters since. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Allianz Asset Management held 785,798 shares of Ginkgo Bioworks worth $7.79M as of Q2 2026.
  • Allianz Asset Management bought 85,282 Ginkgo Bioworks shares in Q2 2026, an estimated $713K.
  • Ginkgo Bioworks made up 0.01% of Allianz Asset Management's portfolio in Q2 2026, its #1197 holding.
  • Allianz Asset Management first reported a position in Ginkgo Bioworks in Q3 2022 and has held it in 11 quarters since.
  • 184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.